A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writ 1 May 2024
X4 Pharmaceuticals has secured US approval for Xolremdi (mavorixafor), for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokat 30 April 2024
Interpharma, the association of research-based pharmaceutical companies in Switzerland, has called on lawmakers to reconsider a cost containment package which i 29 April 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.